Abstract
In addition to centrally regulating electrolyte homeostasis and blood pressure, angiotensin IIhas various general effects on the central nervous system. The existence of renin-angiotensin system components in the brain has been well established. Angiotensin II and other renin-angiotensin system components are synthesized and distributed throughout the brain. Post-ischemic oral administration of a non-hypotensive dose (1/10th of the clinical dose) of angiotensin receptor blocker (ARB) has protective effects on reducing cerebral ischemic injury and improving neurological outcomes. Brain tissue angiotensin II levels transiently increase after reperfusion through the local generation of angiotensin IIand not via the transudation of plasma angiotensin II. Systemic administration of ARBs decreases brain tissue angiotensin II in both the intact and ischemic brain tissue via downregulation of angiotensinogen and angiotensin-converting enzyme mRNA expression, although plasma ARB barely crosses the blood-brain barrier during systemic ARB treatment. Only hypotensive dose of ARB treatment opens leptomeningeal anastomoses. Therefore, systemic ARB treatment shows neuroprotective effects not through increasing collateral perfusion but decreasing brain tissue angiotensin II in a nonhypotensive dose.
Keywords: Brain, cerebral ischemia, renin-angiotensin system, angiotensin type 1 receptor, angiotensin receptor blocker.
Current Hypertension Reviews
Title:Do RAS Inhibitors Protect the Brain from Cerebral Ischemic Injury?
Volume: 9 Issue: 2
Author(s): Naohisa Hosomi, Akira Nishiyama and Masayasu Matsumoto
Affiliation:
Keywords: Brain, cerebral ischemia, renin-angiotensin system, angiotensin type 1 receptor, angiotensin receptor blocker.
Abstract: In addition to centrally regulating electrolyte homeostasis and blood pressure, angiotensin IIhas various general effects on the central nervous system. The existence of renin-angiotensin system components in the brain has been well established. Angiotensin II and other renin-angiotensin system components are synthesized and distributed throughout the brain. Post-ischemic oral administration of a non-hypotensive dose (1/10th of the clinical dose) of angiotensin receptor blocker (ARB) has protective effects on reducing cerebral ischemic injury and improving neurological outcomes. Brain tissue angiotensin II levels transiently increase after reperfusion through the local generation of angiotensin IIand not via the transudation of plasma angiotensin II. Systemic administration of ARBs decreases brain tissue angiotensin II in both the intact and ischemic brain tissue via downregulation of angiotensinogen and angiotensin-converting enzyme mRNA expression, although plasma ARB barely crosses the blood-brain barrier during systemic ARB treatment. Only hypotensive dose of ARB treatment opens leptomeningeal anastomoses. Therefore, systemic ARB treatment shows neuroprotective effects not through increasing collateral perfusion but decreasing brain tissue angiotensin II in a nonhypotensive dose.
Export Options
About this article
Cite this article as:
Hosomi Naohisa, Nishiyama Akira and Matsumoto Masayasu, Do RAS Inhibitors Protect the Brain from Cerebral Ischemic Injury?, Current Hypertension Reviews 2013; 9 (2) . https://dx.doi.org/10.2174/15734021113099990002
DOI https://dx.doi.org/10.2174/15734021113099990002 |
Print ISSN 1573-4021 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6506 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The History and Rationale for Monoclonal Antibodies in the Treatment of Hematologic Malignancy
Current Pharmaceutical Biotechnology Chemical and Pharmacological Significance of 1,4-Dihydropyridines
Current Organic Chemistry Anti-Shock Garments for Obstetric Hemorrhage
Current Women`s Health Reviews Vascular Toxicity of Chemotherapeutic Agents
Current Vascular Pharmacology Improving Pediatric Survival from Resuscitation Events: The Role and Organization of Hospital-based Rapid Response Systems and Code Teams
Current Pediatric Reviews Assessing and Treating Cognitive Impairment in Schizophrenia: Current and Future
Current Pharmaceutical Design Current Landscape of Natural Products against Coronaviruses: Perspectives in COVID-19 Treatment and Anti-viral Mechanism
Current Pharmaceutical Design Loop Diuretics Strategies in Acute Heart Failure: From Clinical Trials to Practical Application
Current Drug Targets Meet the Guest Editor
Combinatorial Chemistry & High Throughput Screening Efficacy and Safety Profile of Aliskiren: Practical Implications for Clinicians
Current Drug Safety The Use of Thiazides in Chronic Kidney Disease
Current Hypertension Reviews Traditional Chinese Medicine - Sea Urchin
Mini-Reviews in Medicinal Chemistry Reviewing the Cardiovascular Complications of HIV Infection After the Introduction of Highly Active Antiretroviral Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Intravenous Immunoglobulin as a Potential Therapy for Refractory Urticaria - A Review
Inflammation & Allergy - Drug Targets (Discontinued) Current Options and Perspectives in the Treatment of Diabetic Neuropathy
Current Pharmaceutical Design Point of NO Return for Nitrergic Nerves in Diabetes: A New Insight into Diabetic Complications
Current Pharmaceutical Design Sevoflurane in Intraoperative and Postoperative Cardiac Surgery Patients. Our Experience in Intensive Care Unit with Sevoflurane Sedation
Current Pharmaceutical Design Regulation of Angiogenesis by the Kallikrein-Kinin System
Current Pharmaceutical Design Hypertension in Patients with Severe Aortic Stenosis: Emphasis on Antihypertensive Treatment and the Risk of Syncope
Current Hypertension Reviews Phytochemical and Pharmacological Insight on Sesamol: An Updated Review
Current Bioactive Compounds